A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT07285304 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG: TS-172

Sponsor

Taisho Pharmaceutical Co., Ltd.